Search
filgotinib (Jyseleca)
Indications:
- refractory rheumatoid arthritis
Dosage:
- 100 mg or 200 mg PO QD
Adverse effects:
- nasopharyngitis (10%)
- 4 uncomplicated herpes zoster cases
- 1 retinal vein occlusion
- no opportunistic infections, active tuberculosis, malignancies, GI perforations, or deaths
- possible impact on sperm parameters (held up FDA approval) [2]
- potential toxicities seen at a high 200 mg dose [2]
Mechanism of action:
- JAK1 inhibitor
Notes:
- Galapagos sole developer [2]
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM correlations
References
- Genovese MC, Kalunian K, Gottenberg JE et al
Effect of Filgotinib vs Placebo on Clinical Response in Patients
With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-
Modifying Antirheumatic Drug TherapyThe FINCH 2 Randomized Clinical
Trial.
JAMA. 2019;322(4):315-325
PMID: 31334793
https://jamanetwork.com/journals/jama/fullarticle/2738551
- Singh JA
Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid
Arthritis.
JAMA. 2019;322(4):309-311
PMID: 31334773
https://jamanetwork.com/journals/jama/fullarticle/2738528
- Gever J
Filgotinib Maintains RA Efficacy for 3 Years, No New Safety Issues.
Looks like FDA blew the call on selective JAK1 inhibitor.
MedPage Today October 28, 2024
https://www.medpagetoday.com/rheumatology/arthritis/112618